Gain Therapeutics, Inc. has announced that Dr. Joanne Taylor will present the company's lead drug candidate, GT-02287, at the upcoming AD/PD™ 2025 Conference in Vienna, Austria. GT-02287 is currently ...
The full abstract can be accessed at the AD/PD online interactive program. The AD/PD™ Conference is an annual event attracting leading medical and scientific professionals from around the world, ...
Phase 1b study ongoing to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of GT-02287 in people with Parkinson’s disease; biomarker analysis to be conducted in Q2 2025 BETHESDA, Md ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results